📰 Activating Construct News
Page 4 - Activating Construct News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Activating Construct. Real-time updates on events, politics, business and more.
April 1, 2023
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) had its price objective trimmed by HC Wainwright from $7.00 to $4.50 in a report released on Wednesday morning, The Fly reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Harpoon Therapeutics’ Q1 2023 earnings at ($0.52) EPS, Q2 2023 earnings […]
March 31, 2023
Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) – Equities researchers at HC Wainwright issued their FY2027 EPS estimates for Harpoon Therapeutics in a research note issued to investors on Wednesday, March 29th. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.23 per share for the year. HC Wainwright has a “Buy” rating […]
March 27, 2023
HPN217 and HPN328 enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million preferred... | March 27, 2023
February 7, 2023
07.02.2023 - SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will present at the virtual SVB ...
December 11, 2022
11.12.2022 - Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses ... Seite 1
August 10, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
August 2, 2022
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 -- Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate...
March 18, 2022
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) had its target price lowered by HC Wainwright from $31.00 to $18.00 in a research report released on Monday morning, The Fly reports. The brokerage currently has a buy rating on the stock. A number of other research firms also recently weighed in on HARP. SVB Leerink cut their […]
March 15, 2022
Zacks Investment Research lowered shares of Harpoon Therapeutics (NASDAQ:HARP – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which harness the power of […]
March 7, 2022
SOUTH SAN FRANCISCO, Calif., March 07, 2022 -- Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and... | March 7, 2022